India’s SunPharma reconsiders Egypt exit, expects 50% growth in sales

The Health Ministry’s decision to raise the prices of meds has driven India’s SunPharma to reconsider their Egypt exit strategy, head of SunPharma Egypt Hany Meshaal told Al Borsa. The company recently launched its own factory in Six of October with an annual capacity of 500 mn, he said, with sales expected to grow to 50% to EGP 120 mn this year from EGP 80 mn in 2016.